# From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management

## TL;DR

BPC-157 is a synthetic peptide that shows promise in healing tissues and managing pain, but more human studies are needed to confirm its effectiveness and safety.

## Contribution

The paper reviews BPC-157's preclinical and limited clinical evidence for tissue repair and pain management, highlighting the need for further clinical trials.

## Key findings

- BPC-157 promotes tissue healing through angiogenesis and collagen synthesis in preclinical models.
- It reduces inflammation and modulates pain via peripheral and dopaminergic mechanisms.
- Pilot human studies suggest potential therapeutic value with no major adverse effects reported.

## Abstract

Body Protective Compound-157 (BPC-157) is a synthetic pentadecapeptide derived from gastric proteins that has demonstrated notable reparative and anti-inflammatory properties across diverse preclinical models. Experimental evidence reveals that BPC-157 supports angiogenesis, collagen synthesis, fibroblast activity, and modulation of nitric oxide pathways, contributing to enhanced healing of muscle, tendon, ligament, bone, and gastrointestinal tissue. Studies also report reduced inflammatory cytokine activity, improved microvascular integrity, and beneficial effects on pain modulation through peripheral and dopaminergic mechanisms. Although animal data indicate favorable safety and pharmacokinetics, human research remains limited to small pilot studies investigating musculoskeletal pain, interstitial cystitis, and intravenous administration, all suggesting potential therapeutic value without reported major adverse effects. However, inconsistent preparation standards, limited clinical validation, and regulatory restrictions underscore the need for rigorous controlled trials. BPC-157 remains a promising candidate for regenerative medicine, yet comprehensive evaluation is required before clinical translation can be recommended.